Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS AND ERECTILE FUNCTION IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART 2)

https://doi.org/10.20996/1819-6446-2012-8-5-626-635

Full Text:

Abstract

Aim. To compare antihypertensive and metabolic effects as well as influence on erectile function (EF) of long-term treatment with carvedilol or bisoprolol in patients with arterial hypertension (HT) of 1-2 degree and overweight/obesity. Material and methods. A total of 105 patients were enrolled into randomized, an open-label comparative stepped trial. The patients were randomized into two groups: the group 1 (n=53) started treatment with carvedilol 25 mg daily and the group 2 (n=52) – with bisoprolol 5 mg daily. If the effect was insufficient a dose of a beta-blocker was doubled, then amlodipine was added in the dose of 5 mg daily with its further increase if necessary or indapamide 1.5 mg daily addition. The follow-up for each patient was 24 weeks. At the start and then 12 and 24 weeks later the frequency of target blood pressure (BP) achievement, body mass index, biochemical indices, ECG and treatment safety were evaluated. Besides, the International Index of EF (IIEF) was calculated with the special questionnaire. Results. The effect of the treatment on BP , body mass index, biochemical parameters, indices of insulin resistance and treatment safety were presented in the first part of the article [1]. IIEF showed increase in the group 1 as compared with both baseline and its state after 12 weeks of the treatment [+2.4±5.0 (p=0.002) for all items of EF questionnaire and +0.67±2.3 (р<0.05) for the 1-5,15 items of EF questionnaire]. Patients of the group 2 showed reduction in IIEF from 12 to 24 weeks of the treatment [-1.8±7.9 (р<0.01) for all items of EF questionnaire and - 0.73±2.7 (р<0.05) for the 1-5,15 items of EF questionnaire]. There were no differences in frequency and severity of adverse events between groups. Conclusion. At similar antihypertensive efficacy , carvedilol, in contrast to bisoprolol, had not only beneficial metabolic effects, but in long-term treatment was able to improve EF in patients with HT and abdominal obesity.

About the Authors

S. Y. Martsevich
State Research Center for Preventive Medicine
Russian Federation

PhD, MD, Professor , Head of Department of Preventive Pharmacotherapy



S. N. Tolpigina
State Research Center for Preventive Medicine
Russian Federation
PhD, MD, Leading researcher of Department of Preventive Pharmacotherapy


References

1. Martsevich S.Y., Tolpygina S.N. on behalf of the CABRIOLET trial working group. Comparison of the influence of long-term treatment based on carvedilol or bisoprolol on metabolic parameters in hypertensive patients with overweight or obesity Results of the randomized open-label parallel-groups steppped trial CABRIOLET (part I). Rational Pharmacother Card 2012;8(4):488–499. (Марцевич С.Ю., Толпыгина С.Н. от имени рабочей группы по проведению исследования КАБРИОЛЕТ. Сравнение влияния длительной терапии, основанной на карведилоле или бисопрололе, на метаболические параметры у больных артериальной гипертонией и избыточной массой тела или ожирением. Результаты рандомизированного открытого параллельного ступенчатого исследования КАБРИОЛЕТ (часть 1). РФК 2012;8(4):488–499).

2. The Task Force on Beta–Blockers of the European Society of Cardiology. Expert consensus document on β–adrenergic receptor blockers. Eur Heart J 2004;25:1341–62.

3. Nusbaum M.R. Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc 2002; 102 (12 Suppl 4): 1–6.

4. Burchardt M., Burchardt T., Baer L. et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188–1191.

5. Roth A., Kalter–Leibovici O., Kerbis Y. et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1412 Israeli men. Clin Car-diol 2003;26(1):25–30.

6. Fogari R., Zoppi A., Poletti L., et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14(1):27–31.

7. Mickley H. Incidence and treatment of sexual dysfunction in heart disease. Ugeskr Laeger 2002; 164(41): 4760–4764.

8. Ralph D., McNicholas T. UK management guidelines for erectile dysfunction. BMJ 2000; 321(19): 499– 503.

9. Wassertheil–Smoller S., Blaufox M.D., Oberman A. et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern M 1991; 114:613–20.

10. Lever A.F., Brennan P.J. Medical research council trial of treatment of hypertension in older adults. Clin Exp Hypertens 1993;15: 941–949.

11. Rosen R.C., Riley A., Wagner G. et al. The international index of erectile function (IIEF): multidimentional scale for the assessment of erectile dysfunction. Urology 1997; 49(6): 822–830.

12. Barrett-Connor E. Cardiovascular risk stratification and cardiovascular risk factors associated ith erectile dysfunction: assessing cardiovascular risk in men with erectile dysfunction. Clin Cardiol 2004; 27(4 Suppl 1): I8–13.

13. Roth A., Kalter–Leibovici O., Kerbis Y. et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1412 Israeli men. Clin Car-diol 2003;26(1):25–30.

14. Van Bortel L.M., Duprez D. Clinical application of arterial stiffnes, Task Forse III: recommendations for user procedures. Am J Hypertens 2002;15 (5): 445–52.

15. Cellek S., Rodrigo J., Lobos E. et al. Selective nitrergic neurodegeneration in diabetes mellitus – a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128(8):1804–1812.

16. Kung C.F., Luscher T.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25(2): 194–200.

17. Li J.S., Sharifi A.M., Schiffrin E.L. Effect of AT, angiotensin-receptor blockade on structure and function of small arteries in SHR. J Cardiovasc Pharmacol 1997; 30(1): 75–83.

18. Linder L., Kiowski W., Buhler F.R., Luscher T.F. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81(6): 1762–1767.

19. Taddei S., Virdis A., Ghiadoni L., et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29(1 Pt 2):274–279.

20. Jackson G., Giuilano F. Moderator's introduction. Eur Heart J 2002; 4 Suppl H: 1–6.

21. Mickley H. Incidence and treatment of sexual dysfunction in heart disease. Ugeskr Laeger 2002; 164(41): 4760–4764.

22. Okabe H., Hale T.M., Kumon H., Heaton J.P., Adams M.A. The penis is not protected: in hypertension there are vascular changes in the penis which are similar to those in other vascular beds. Int J Impot Res 1999; 11(3): 133–140.

23. Toblli J.E., Stella I., Inserra F., et al. Morphological changes in cavernous tissue in spontaneously hypertensive rats. Am J Hypertens 2000;13(6 Pt 1): 686–692.

24. Shal'nova S.A., Martsevich S.Iu., Deev A.D., et al. First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD). Kardiologiia 2008;48(8):28–33. Russian (Шальнова С.А., Марцевич С.Ю., Деев А.Д. и др. Первые результаты многоцентрового рандомизированного клинического исследования по применению препарата Акридилол® в комбинированной терапии у больных артериальной гипертонией и ожирением или сахарным диабетом 2-го типа (АККОРД). Кардиология 2008;(8):28–33).

25. Martsevich S.Y., Kutishenko N.P., Shilova E.V. Comparison of therapies based on carvedilol and metoprolol in hypertensive patients with overweight or obesity. The first results of CAMELLIA trial. Rational Pharmacother Card 2009;(1):23–27. Russian (Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В., и др. от имени рабочей группы по проведению исследования «Камелия». Сравнение терапии, основанной на карведилоле или метапрололе, у больных артериальной гипертонией и избыточной массой тела/ожирением. Первые результаты исследования «Камелия». РФК 2009; (1): 23–27).

26. Torp-Pedersen C., Metra M., Charlesworth A. et al. COMET investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007;93(8):968–73.

27. Sponer G., Bartsch W., Strein K., et al. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987; 9(3):317–327.

28. Weber K., Bohmeke T., van der Does R., Taylor S.H. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996; 10(2):113–117.

29. Lysko P.G., Webb C.L., Gu J.L., et al. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000;36(2):277–281.

30. Niskanen L., Laaksonen D.E., Punnonen K. et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6: 208–15.

31. Esposito K., Giugliano F., Di Palo C. et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291(24): 2978–84.

32. Pourmand G., Alidaee M.R., Rasuli S. et al. Do cigarette smokers with erectile dysfunction benefit from stopping? A prospective study. BJU Int 2004; 94: 1310–3.

33. Saltzman E.A., Guay A.T., Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: A clinical observ. J Urol 2004;172: 255–8.

34. Hale T.M., Okabe H., Bushfield T.L. et al. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol 2002;168(1):348–54.

35. Swanson-Fisher R.W., Clover K. Compliance in the treatment of hypertension. A need for action. Am J Hypertens 1995; 8(10 Pt 2): 82S–88S.

36. Rosen R.C. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1997; 1: 47–51.

37. Weinberger M.H. Lowering blood pressure in patients without affecting quality of life. Am J Med 1989; 86(1B):94–97.

38. Prisant L.M., Carr A.A., Bottini P.B. et al. Sexual dysfunction with antihypertensive drugs. Arch Intern Med 1994; 154(7): 730–736.

39. Freis E.D. Current status of diuretics, β-blockers, α-blockers and α-, β-blockers in the treatment of hypertension. Med Clin North Am 1997; 81: 1305–17.

40. Keene L.C., Davies P.H. Drug related erectile dysfunction. Adverse Drug React Toxicol Rev 1999; 18: 5–24.

41. Franzen D., Metha A., Seifert N. et al. Effects of beta–blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001;13(6):348–51.

42. Broekman C.P., Haensel S.M., Van de Ven L.L., Slob A.K. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 29: 325–31.

43. Ritter J.M. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001; 38(Suppl 3): S13–6.

44. Arabidze G.G., Arabidze Gr. G. Antihypertensive therapy and sexual function in men. Klinicheskaya Farmakologiya i Terapiya 1999;(3):49–52. Russian (Арабидзе Г.Г., Арабидзе Гр. Г. Антигипертензивная терапия и половая функция у мужчин. Клиническая Фармакология и Терапия 1999;(3):49–52).

45. Vertkin A.L. Erectile dysfunction in the practice of a cardiologist. In: Erectile dysfunction, diagnosis and treatment. Collected articles. M.: Praktika; 2004: 82–96. Russian (Верткин А.Л. Эректильная дисфункция в практике врача-кардиолога. В: Эректильная дисфункция, диагностика и лечение. Сборник научных статей. М.: Практика; 2004: 82–96).

46. DeBusk R., Drory Y., Goldstein I. et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86 (2A): 62F–68F.


For citation:


Martsevich S.Y., Tolpigina S.N. COMPARISON OF THE INFLUENCE OF LONG-TERM TREATMENT BASED ON CARVEDILOL OR BISOPROLOL ON METABOLIC PARAMETERS AND ERECTILE FUNCTION IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY RESULTS OF THE RANDOMIZED OPEN-LABEL PARALLEL-GROUPS STEPPED TRIAL CABRIOLET (PART 2). Rational Pharmacotherapy in Cardiology. 2012;8(5):626-635. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-5-626-635

Views: 747


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)